Literature DB >> 9362443

Novel BRCA1 mutations and more frequent intron-20 alteration found among 236 women from Western Poland.

K Sobczak1, P Kozłowski, M Napierała, J Czarny, M Woźniak, M Kapuścińska, M Lośko, M Koziczak, A Jasińska, J Powierska, R Braczkowski, J Breborowicz, D Godlewski, A Mackiewicz, W Krzyzosiak.   

Abstract

Three different novel BRCA1 mutations, five independent cases of the same 12 bp insertion-duplication in intron-20 and two novel rare BRCA1 sequence variants were identified among 122 Polish women with positive, in most cases moderate family history of breast and/or ovarian cancer, 80 controls and 34 unselected breast cancer tissue specimens. All mutations and variants were germline. The 4153 delA frameshift mutation, the Tyr105Cys missense mutation and two cases of the alteration in intron-20 were found in the group of healthy women with positive family history. Two other cases of the intronic insertion were found in unselected controls. Their carriers had no family history of breast or ovarian cancer but other cancers occurred in their families. The 1782 Trp/STOP nonsense mutation and one case of the insertion in intron-20 were first found in tissue specimens of breast cancer patient and breast/ovarian cancer patient, respectively. Their carriers also had no family history of breast or ovarian cancer. The distribution of the insertion in intron-20 in analysed groups and results of RT-PCR experiments suggest a less prominent role for this variant considered earlier a splicing mutation. This study shows also, that more population-oriented research is needed, involving women with less profound or even no family history of breast and ovarian cancer, to better understand the role and significance of different BRCA1 variants and mutations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9362443     DOI: 10.1038/sj.onc.1201360

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Combined SSCP/duplex analysis by capillary electrophoresis for more efficient mutation detection.

Authors:  P Kozlowski; W J Krzyzosiak
Journal:  Nucleic Acids Res       Date:  2001-07-15       Impact factor: 16.971

2.  RNA structure analysis assisted by capillary electrophoresis.

Authors:  Krzysztof Sobczak; Wlodzimierz J Krzyzosiak
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

3.  Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.

Authors:  B Górski; T Byrski; T Huzarski; A Jakubowska; J Menkiszak; J Gronwald; A Pluzańska; M Bebenek; L Fischer-Maliszewska; E Grzybowska; S A Narod; J Lubiński
Journal:  Am J Hum Genet       Date:  2000-04-28       Impact factor: 11.025

4.  BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.

Authors:  J T Bergthorsson; B Ejlertsen; J H Olsen; A Borg; K V Nielsen; R B Barkardottir; S Klausen; H T Mouridsen; K Winther; K Fenger; A Niebuhr; T L Harboe; E Niebuhr
Journal:  J Med Genet       Date:  2001-06       Impact factor: 6.318

5.  BRCA1 4153delA founder mutation in Russian ovarian cancer patients.

Authors:  Nadezhda Yu Krylova; Oksana S Lobeiko; Anna P Sokolenko; Aglaya G Iyevleva; Maxim E Rozanov; Natalia V Mitiushkina; Madina M Gergova; Tatiana V Porhanova; Adel F Urmancheyeva; Sergey Ya Maximov; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2006-09-15       Impact factor: 2.857

6.  BRCA1 testing.

Authors:  Bohdan Górski; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2008-06-15       Impact factor: 2.857

7.  Prevalence of the BRCA1 c.68_69delAG (BIC: 185delAG) mutation in women with breast cancer from north-central Poland and a review of the literature on other regions of the country.

Authors:  Martyna Hartwig; Hanna Janiszewska; Aneta Bąk; Maria Pilarska; Marta Heise; Anna Junkiert-Czarnecka; Ryszard Laskowski; Olga Haus
Journal:  Contemp Oncol (Pozn)       Date:  2013-03-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.